In the tumor, an ectonucleotidase enzymatic activity assay [29] of tissue oleclumab penetrance demonstrated a decrease in CD73 enzymatic activity 20 days after the first oleclumab dose in tissues from all 4 patients with evaluable paired biopsies who received oleclumab monotherapy (n = 3) or oleclumab in combination with durvalumab (n = 1) in the escalation phase (Fig. 2a). The gene discussed is NT5E; the disease is neoplasm.